FilingSEC EDGAR8-K
MIRA Pharmaceuticals Submits Phase 2a Protocol for Ketamir-2
· SEC accepted
StagePhase 2a
Filing content
The company submitted its Phase 2a clinical protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy to the Institutional Review Board following FDA review.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…